Literature DB >> 7988431

Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells.

S Eguchi1, Y Hirata, H Iwasaki, K Sato, T X Watanabe, T Inui, K Nakajima, S Sakakibara, F Marumo.   

Abstract

Vascular smooth muscle cells (VSMC) from rat aorta possess specific receptors for a novel potent vasorelaxant peptide, adrenomedullin (AM). To elucidate its receptor coupling to guanine nucleotide-binding stimulatory protein and the structural requirement of the AM molecule to its vascular receptors, we have studied the effects of guanine nucleotides on [125I]human (h) AM binding and adenylate cyclase activity in cultured rat VSMC, and the effects of various synthetic hAM analogs on [125I]hAM binding and the cAMP response. Guanosine 5'-O-(3-thiotriphosphate) dose dependently inhibited [125I]hAM binding to rat VSMC membranes. hAM stimulated adenylate cyclase activity, and its effect was additive with GTP. hAM-induced cAMP formation was abrogated by pretreatment with cholera toxin, but not by that with pertussis toxin. Intact hAM-(1-52)-NH2 and N-terminal truncated derivatives [hAM-(13-52)-NH2, hAM-(16-52)-NH2] almost equally inhibited [125I]hAM binding and stimulated cAMP formation, whereas removal of C-terminal Tyr52 residue [hAM-(1-51)-NH2] remarkably decreased receptor-binding activity and the cAMP response. The effects of hAM-(1-52)-OH, hAM-(1-51)-OH, and a linear hAM analog ([carbamoylmethyl-Cys16,21]hAM-NH2) were far less potent on receptor binding and the cAMP response than that of hAM-(1-52)-NH2. The C-terminal fragment [hAM-(33-52)-NH2] and the N-terminal fragment [hAM-(1-10)-OH] had neither receptor-binding nor adenylate cyclase activity. hAM-(22-52)-NH2 had no agonistic effect, but showed an antagonistic effect on the hAM-induced cAMP response. These data suggest that vascular AM receptors are functionally coupled to adenylate cyclase via guanine nucleotide-binding stimulatory protein. Studies of the structure-activity relationship of hAM revealed that the cyclic structure formed by the disulfide bridge and amidation of the C-terminal residue of the AM molecule are critical for receptor binding and subsequent cAMP generation and suggest that the C-terminal fragment hAM-(22-52)-NH2 may be an antagonist for vascular AM receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988431     DOI: 10.1210/endo.135.6.7988431

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  26 in total

1.  CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.

Authors:  P Hasbak; A Sams; S Schifter; J Longmore; L Edvinsson
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

2.  Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: role of adrenomedullin and adrenomedullin binding protein-1.

Authors:  Shaolong Yang; Mian Zhou; Irshad H Chaudry; Ping Wang
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 3.  The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors.

Authors:  Debbie L Hay; Alex C Conner; Stephen G Howitt; David M Smith; David R Poyner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

4.  Possible involvement of adrenomedullin in lipopolysaccharide-induced small-intestinal motility changes in conscious rats.

Authors:  Sarwar Hussain; Reiko Miyazawa; Takeshi Tomomasa; Hiroaki Kaneko; Atsushi Takahashi; Toshio Watanabe; Hirokazu Arakawa; Akihiro Morikawa
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

5.  Influence of CGRP (8-37), but not adrenomedullin (22-52), on the haemodynamic responses to lipopolysaccharide in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

6.  Rat-2 fibroblasts express specific adrenomedullin receptors, but not calcitonin-gene-related-peptide receptors, which mediate increased intracellular cAMP and inhibit mitogen-activated protein kinase activity.

Authors:  H A Coppock; A A Owji; C Austin; P D Upton; M L Jackson; J V Gardiner; M A Ghatei; S R Bloom; D M Smith
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

7.  Identification of key residues involved in adrenomedullin binding to the AM1 receptor.

Authors:  H A Watkins; M Au; R Bobby; J K Archbold; N Abdul-Manan; J M Moore; M J Middleditch; G M Williams; M A Brimble; A J Dingley; D L Hay
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  Molecular Mechanisms of Class B GPCR Activation: Insights from Adrenomedullin Receptors.

Authors:  Michael L Garelja; Maggie Au; Margaret A Brimble; Joseph J Gingell; Erica R Hendrikse; Annie Lovell; Nicole Prodan; Patrick M Sexton; Andrew Siow; Christopher S Walker; Harriet A Watkins; Geoffrey M Williams; Denise Wootten; Sung H Yang; Paul W R Harris; Debbie L Hay
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-26

9.  CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

Authors:  D L Hay; S G Howitt; A C Conner; M Schindler; D M Smith; D R Poyner
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

10.  Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure.

Authors:  Wesley H Self; Alan B Storrow; Oliver Hartmann; Tyler W Barrett; Gregory J Fermann; Alan S Maisel; Joachim Struck; Andreas Bergmann; Sean P Collins
Journal:  Am J Emerg Med       Date:  2015-10-24       Impact factor: 2.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.